Fetal Neonatal Alloimmune Thrombocytopenia



Fetal Neonatal Alloimmune Thrombocytopenia


Victoria Lindstrom Chase

Michael J. Paidas



Introduction

Fetal and neonatal thrombocytopenia is defined by a platelet count less than 150,000/µL. Thrombocytopenia can be the result of a variety of different etiologies ranging from immunologic disorders, to antenatal infections, to genetic conditions. Platelet counts above 50,000/µL are unlikely to cause significant sequelae. However, when the fetal platelet count drops below this threshold, significant sequela may arise, with the most serious being spontaneous intracranial bleeding. Of fetuses and neonates with severe thrombocytopenia, defined by a platelet count less than 50,000/µL, fetal and neonatal alloimmune thrombocytopenia (FNAIT) is the most common cause.


Etiology

FNAIT is a pregnancy complication that affects a fetus or baby’s platelets and can lead to serious fetal or neonatal morbidity and mortality. Platelets have protein on their surface called human platelet antigens (HPAs) that are both maternally and paternally inherited in an autosomal codominant fashion. In pregnancy and at the time of delivery, fetal platelets enter maternal circulation. If the maternal immune system identifies foreign, paternally inherited HPAs, maternal alloantibodies against the fetal HPAs may occur. The maternal immunoglobulin (Ig) G antibodies produced then cross the placenta and invoke fetal platelet destruction (Figure 23.1).

FNAIT is considered the platelet equivalent of hemolytic disease of the fetus and newborn (HDFN; and see Chapter 22). However, there are important differences between the two diseases. Approximately 2% of women are HPA-1-negative, as compared to approximately 10% of Rh-negative women. FNAIT frequently occurs in the first pregnancy, in contrast to HDFN, in which clinically affected fetuses and newborns rarely occur in the first pregnancy, but disease is manifested in the second and subsequent pregnancies. Sensitization following an incompatible transfusion rarely occurs with the HPA-1a antigen, whereas anti-D is the most common antibody response during incompatible transfusions. Routine antenatal screening for FNAIT does not exist but does for Rh phenotyping. Prevention does not exist for FNAIT but does for HDFN related to anti-D, namely antenatal and postnatal RhIG (anti-D).

The incidence of FNAIT is 1 in 1000 to 1 in 2000 live births.1,2 Severity of thrombocytopenia ranges from clinically asymptomatic neonates to fetuses or neonates with intracranial hemorrhage (ICH) and/or death.3 Death or long-term neurological damage resulting from ICH that occurs at or soon after delivery is historically quoted at 25%4 with in utero spontaneous ICH occurring in 5% to 10% of pregnancies.5 In more contemporary literature of pregnancies affected by FNAIT, the rate of ICH has been reported as 8.9% and mortality approximately as 1%.6

As mentioned, FNAIT may occur in the first pregnancy of an at-risk couple. The fetal bleeding risk is a result of thrombocytopenia and, in mouse studies, maternal alloantibody mediated damage to vascular integrity and angiogenesis.7,8,9 The severity of thrombocytopenia differs depending on the platelet antigen involved,10 may worsen with increasing gestation,3 and is more severe if prior pregnancies have been affected.


Biologic Activity of Human Platelet Antigens

Over 30 HPAs have been identified (Table 23.1). They are carried on platelet membrane glycoproteins (GP) 1a-V-IX, more commonly known as the
von Willebrand receptor; GPIIb/IIIa, an αIIb/β3 integrin and fibrinogen receptor; heparin platelet (HP) Ia/IIa, a collagen receptor; and cluster of differentiation (CD) 109, a glycosylphosphatidylinositol-anchored protein. Platelet glycoproteins function by interacting with extracellular matrix protein and coagulation factors to achieve hemostasis. Glycoprotein IV, a class B scavenger receptor, can elicit a FNAIT-like clinical picture. Deficiency in this glycoprotein is more common in those with African or Asian descent (Figure 23.2).11






Many HPAs are biallelic and codominant. The most commonly implicated platelet antibody in FNAIT is due to anti-HPA-1a alloimmunization in mothers who are HPA-1b homozygous, which is responsible for approximately 80% of cases of FNAIT in non-Hispanic white women.3 The HPA-1a and HPA-1b alleles are variants of the β3 integrin molecule on glycoprotein IIIa which are a result of a substitution of a proline for leucine base at amino acid 33.12 The next most common antibodies implicated in FNAIT in non-Hispanic whites are against HPA-5a and HPA-15. In contrast, in Asian women, HPA-4a, HPA-6a, and HPA-21b incompatibility is more frequently causative.11,13

Additionally, an increased immunologic susceptibility to alloimmunization has been associated with certain human leukocyte antigens (HLAs). HLA-DRB3*0101 is an example of one of these HLAs studied due to its association with alloimmunization in women who are HPA-1a-negative. Women who carry one or two copies of HLA-DBR3*0101 and are delivering a HLA-1a-positive child have a 12.7% risk of alloimmunization versus a 0.5% risk in those negative for the allele.12 An increased risk of alloimmunization is also seen in women with Dw52a, DQB1*0201, and DR6 alleles.14










Jun 19, 2022 | Posted by in OBSTETRICS | Comments Off on Fetal Neonatal Alloimmune Thrombocytopenia
Premium Wordpress Themes by UFO Themes